Indian anticoagulants market is estimated to grow at a CAGR of 8.8% during the forecast period. Growing CVD incidences have been leading to increasing demand for anticoagulants in the country. As per the American Heart Association (AHA), in India, the estimated prevalence of CVDs was estimated to be 54.5 million in 2016. One in 4 deaths in the country is reported due to CVDs with stroke and ischemic heart disease that are responsible for more than 80% of this burden. This is resulting in an increasing demand for anticoagulant treatment for acute coronary syndromes. It is effective to treat and prevent pulmonary emboli and venous thrombosis. Vitamin K antagonists are one of the oral anticoagulants demonstrated for long-term therapy of patients suffering from CHD, primarily after an acute coronary syndrome (ACS).

Visit for Global Anticoagulants Market Report at: https://www.omrglobal.com/industry-reports/anticoagulants-market

The market is segmented based on type and application. Based on type, the market is classified into novel oral anticoagulants (NOACs), vitamin k antagonist, and heparin, and low molecular weight heparin (LMWH). To minimize the risk of stroke in appropriate atrial fibrillation (AF) patients, NOACs are now the ideal suggested drug class compared to warfarin, except for patients suffering from moderate to severe mitral stenosis or an artificial heart valve. NOACs comprises edoxaban, dabigatran, apixaban, and rivaroxaban. Based on application, the market is classified into a pulmonary embolism, atrial fibrillation/myocardial infarction (heart attack), deep vein thrombosis, and others. 

Some prominent players in the market include Cipla Ltd., Bristol Myers Squibb Co., Pfizer Inc., Daiichi Sankyo Co. Ltd., and Boehringer Ingelheim GmbH. The market players are adopting some crucial strategies such as product launches and mergers and acquisitions. For instance, in October 2019, Morepen Labs has added three new drugs, including UDCA (for liver ailments), Rivaroxaban (cardiac segment), and Vildagliptin (diabetes segment) to its active pharmaceutical ingredients (API) portfolio. Rivaroxaban is an anticoagulant which is a blood thinner. 

Research Methodology

The market study of the Indian anticoagulants market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Indian Anticoagulants Market Research and Analysis by Type
2. Indian Anticoagulants Market Research and Analysis by Application

The Report Covers

• Comprehensive research methodology of the Indian anticoagulants market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the Indian anticoagulants market.
• Insights about market determinants that are stimulating the Indian anticoagulants market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.